[Autologous stem cell transplantation in systemic sclerosis]

Area of Science:

• Immunology
• Hematology
• Rheumatology

Background:

• Autologous hematopoietic stem cell transplantation (HSCT) is a recognized treatment for severe systemic sclerosis (SSc).
• Randomized controlled trials confirm HSCT's superiority over cyclophosphamide pulse therapy for SSc.
• HSCT carries a significant treatment-related mortality risk of approximately 10%.

Purpose of the Study:

• To evaluate the efficacy and safety of HSCT in severe systemic sclerosis (SSc).
• To explore potential mechanisms of action for HSCT in SSc.
• To identify strategies for reducing HSCT-related toxicity and improving patient outcomes.

Main Methods:

• Review of case series and randomized controlled trials comparing HSCT with cyclophosphamide pulse therapy.
• Analysis of treatment-related mortality and patient outcomes.
• Exploration of potential immunological mechanisms, including regulatory T-cell function.

Main Results:

• HSCT demonstrates superior efficacy compared to cyclophosphamide pulse therapy in SSc patients.
• HSCT is associated with approximately 10% treatment-related mortality.
• The precise mechanisms of HSCT action in SSc remain unclear, with limited impact on profibrotic cytokines or autoantibodies observed.

Conclusions:

• HSCT is an effective treatment for severe SSc, but its associated mortality necessitates further research.
• Future studies should focus on optimizing HSCT regimens to minimize toxicity and enhance early accessibility for high-risk patients.
• A deeper understanding of SSc pathogenesis and HSCT's immunological effects is crucial for therapeutic advancement.